CD276 and neoplasm: demonstrated that using the anti-B7-H3 antibody 8H9 can shift cellular metabolism from glycolysis to oxidative phosphorylation, and they suggested that anti-B7-H3 blockade may alter tumor glucose metabolism through reactive oxygen species-mediated pathways by measuring cellular ROS levels in A549 cells treated with the anti-B7-H3 antibody using fluorescence probes (55).